Whenever companies announce a deal, managements try to paint it as a great move for each shareholder group. Experience says that is rarely the case, but Teva Pharmaceuticals' (Nasdaq:TEVA) acquisition of Cephalon (Nasdaq:CEPH) really could be a case where that is true. This deal solves significant, but different, problems for each company.

Tutorial: Mergers And Acquisitions 101

The Terms Of The Deal
Unlike Valeant's (NYSE:VRX) attempt at a hostile bid (or its thus far unsuccessful attempt to find a friendly agreement with Cephalon's board), Teva pursued a friendly offer and both boards agreed to it unanimously. Teva will acquire Cephalon in an all-cash deal that pays Cephalon shareholders $81.50 - 12% more than what Valeant had offered. The deal amounts to about $6.8 billion for Teva, which will have to raise debt for the bid.

Not Great, But Better
Cephalon shareholders may still grumble at the terms of the deal. After all, less than six times trailing EBITDA and about two times trailing revenue is not an exciting premium. What's more, in recent memory Pfizer (NYSE:PFE) paid for more for King and Abbott (NYSE:ABT) paid for Kos.

Still, Cephalon shareholders should realize that this was about as good a deal as they could have hoped for in a buyout. The company has some promise with Nuvigil, Fentora, and Treanda, but there just is not enough in the pipeline to really make for a lot of excitement or a rich valuation. Frustrating as it may be, this deal basically maximizes the value Cephalon had as a going concern with none of the ongoing execution risk. (For more, see Mergers And Acquisitions: Understanding Takeovers.)

A Smart Move for Teva
With recent news from Biogen Idec (Nasdaq:BIIB) casting doubt on Teva's long-term prospects in the multiple sclerosis franchise, and a dearth of major patent expirations after 2013, Teva needed to do something to change up its business. The acquisition of Cephalon will give Teva more than 20 branded drugs, less risk on the MS front (since that will be a smaller part of the business) and an interesting generics business within Cephalon (Mepha, acquired by Cephalon about a year ago). What's more, it should be accretive more or less immediately.

A New Teva?
It will be interesting to see where Teva goes in the next few years. Major pharmaceutical companies like Novartis (NYSE:NVS) and Sanofi-Aventis (NYSE:SNY) have expanded into generics as a way of adding a little more predictability to the business models and better leveraging the sales infrastructure.

Will Teva now try to bulk up its branded business even further, to take advantage of the growth and margins present there, and/or find a value-accreting use of cash? It is a risky move, but the fact remains that reimbursement for branded drugs is still very strong, and there are rich rewards to developing successful compounds.

The real question may be how much more Teva will pay for its expansion plans. Teva trades at a premium to many pharmaceutical companies, and that could make its shares useful as a currency. That said, recent deals have been cash-and-carry, so Teva may find its options more limited on that basis. (For more, see Pharmaceutical Phenoms: America's Best Selling Medicines.)

The Bottom Line
Teva is a borderline buy candidate. There is definitely value here, and this Cephalon deal improves the company's prospects. There are other, cheaper, ideas out there for investors to consider, but Teva is definitely worthy of consideration. (For more, see Teva's Rocky Road.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  4. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  5. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  6. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  7. Stock Analysis

    The Top 5 Micro Cap Alternative Energy Stocks for 2016 (AMSC, SLTD)

    Follow a cautious approach when purchasing micro-cap stocks in the alternative energy sector. Learn about five alternative energy micro-caps worth considering.
  8. Stock Analysis

    Analyzing Porter's Five Forces on Under Armour (UA)

    Learn about Under Armour and how it differentiates itself in the competitive athletic apparel industry in light of the Porter's Five Forces Model.
  9. Stock Analysis

    The Biggest Risks of Investing in Qualcomm Stock (QCOM, BRCM)

    Understand the long-term fundamental risks related to investing in Qualcomm stock, and how financial ratios also play into the investment consideration.
  10. Stock Analysis

    The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

    Learn the largest risks to investing in Johnson & Johnson through fundamental analysis and other potential risks. Also discover how JNJ compares to its peers.
RELATED FAQS
  1. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  2. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  3. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  4. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  5. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
  6. What is the formula for calculating earnings per share (EPS)?

    Earnings per share (EPS) is the portion of a company’s profit that is allocated to each outstanding share of common stock, ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center